Prof. Dr. med. Adrian Merlo - Neurochirurgie, Bern - Publikationen

Cordier D, Krolicki L, Morgenstern A, Merlo A.
Semin Nucl Med. 2016 May;46(3):243-9.

Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D.
J Nucl Med. 2015 Nov;56(11):1748-51.

Grzmil M, Huber RM, Hess D, Frank S, Hynx D, Moncayo G, Klein D, Merlo A, Hemmings BA. J Clin Invest. 2014 Feb;124(2):742-54.

Schulte A, Liffers K, Kathagen A, Riethdorf S, Zapf S, Merlo A, Kolbe K, Westphal M, Lamszus K. Neuro Oncol. 2013 Oct;15(10):1289-301.

Berberat J, Eberle B, Rogers S, Boxheimer L, Lutters G, Merlo A, Bodis S, Remonda L. Acta Radiol. 2013 Jun;54(5):576-80.

Huber RM, Rajski M, Sivasankaran B, Moncayo G, Hemmings BA, Merlo A.
PLoS One. 2013;8(2):e57793.

Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merlo A, Pollack JR, Wong AJ. Oncogene. 2013 May 23;32(21):2670-81.

Tchorz JS, Tome M, Cloëtta D, Sivasankaran B, Grzmil M, Huber RM, Rutz-Schatzmann F, Kirchhoff F, Schaeren-Wiemers N, Gassmann M, Hemmings BA, Merlo A, Bettler B. Cell Death Dis. 2012 Jun 21;3:e325.

Wang Y, Moncayo G, Morin P Jr, Xue G, Grzmil M, Lino MM, Clément-Schatlo V, Frank S, Merlo A, Hemmings BA. Oncogene. 2013 Feb 14;32(7):872-82.

Rogers S, Merlo A, Berberat J, Bodis S. In Regard McDonald et al., to Pattern of Failure After Limited Margin Radiotherapy and Temozolomide for Glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).

Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther. 2011 Jun;10(6):1102-12. Epub 2011 Apr 6.

Grzmil M, Morin P Jr, Lino MM, Merlo A, Frank S, Wang Y, Moncayo G, Hemmings BA. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res. 2011 Mar 15;71(6):2392-402. Epub 2011 Mar 14.

Brellier F, Ruggiero S, Zwolanek D, Martina E, Hess D, Brown-Luedi M, Hartmann U, Koch M, Merlo A, Lino M, Chiquet-Ehrismann R. SMOC1 is a tenascin-C interacting protein over-expressed in brain tumors. Matrix Biol. 2011 Apr;30(3):225-33.

Lino MM, Merlo A, Boulay JL. Notch signaling in glioblastoma: a developmental drug target? BMC 2010 8:72.

Lino MM, Merlo A. PI3Kinase signaling in glioblastoma. J Neurooncol. 2011 Jul;103(3):417-27. Epub 2010 Nov 10.

Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 2010 May 26;10:34.

Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Mäcke H, Müller-Brand J, Merlo A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J Neurooncol. 2010 Mar 10. [Epub ahead of print].

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. Epub 2010 Feb 16

Martina E, Degen M, Rüegg C, Merlo A, Lino MM, Chiquet-Ehrismann R, Brellier F. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. FASEB J. 2010 Mar;24(3):778-87. Epub 2009 Nov 2.

Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, Merlo A, Lino MM. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One. 2009 Oct 13;4(10):e7443.

Boulay JL, Ionescu MC, Sivasankaran B, Labuhn M, Dolder-Schlienger B, Taylor E, Morin P Jr, Hemmings BA, Lino MM, Jones G, Maier D, Merlo A. The 10q25.3-26.1 G protein-coupled receptor gene GPR26 is epigenetically silenced in human gliomas. Int J Oncol. 2009 Nov;35(5):1123-31.

Graeni C, Stepper F, Sturzenegger M, Merlo A, Verlaan DJ, Andermann F, Baumann CR, Bonassin F, Georgiadis D, Baumgartner RW, Rouleau GA, Siegel AM. Inherited cavernous malformations of the central nervous system: clinical and genetic features in 19 Swiss families. Neurosurg Rev. 2010 Jan;33(1):47-51. Epub 2009 Sep 17.

Liu J, Lu H, Ohgaki H, Merlo A, Shen Z. Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer. 2009 Aug 4;9:268.

Lino M, Merlo A. Translating Biology into Clinic: the case of glioblastoma. Curr Opin Cell Biol. 21:311-6, 2009.

Jost G, Zimmerer S, Frank S, Cordier D, Merlo A. Intradural spinal metastasis of renal cell cancer. Report of a case and review of 26 published cases. Acta Neurochir 151: 815-21, 2009.

Boulay JL, Stiefel U, Taylor E, Dolder B, Merlo A, Hirth F. Loss of heterozygosity of TRIM3 in malignant gliomas. BMC Cancer 9:71, 2009.

Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Ionescu M, Tolnay M, Mergenthaler S, Miserez AR, Kiss R, Lino MM, Chiquet-Ehrismann R, Merlo A, Boulay JL. Tenascin-C is a novel RBPJκ-induced target gene for Notch signaling in gliomas.

Mueller AA, Saldamli B, Stübinger S, Walter C, Flückiger U, Merlo A, Schwenzer-Zimmerer K, Zeilhofer HF, Zimmerer S. Cancer Res 69:458-65, 2009.Oral bacterial cultures in non-traumatic brain abscess. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 107: 469-76 2009.

Egler V, Korur S, Failly M, Boulay JL, Imber R, Lino MM, Merlo A. Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioma Cell Death. Clin Cancer Res 14: 3132-40, 2008.

Fluri F, Engelter ST, Wasner M, Stierli P, Merlo A, Lyrer PA. The probability of restenosis, contralateral disease progression and late neurological events following carotid endarterectomy: a long-term follow up study. Cerebrovasc Dis. 26: 654-8, 2008.

Cordier D, Wasner MG, Gluecker T, Gratzl O, Merlo A. Acute paraplegia following myelography: decompensation of a thoracic disc. Br J Neurosurg 22: 684-6, 2008.

Conen A, Walti LN, Merlo A, Fluckiger U, Battegay M, Trampuz A. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 47: 73-82, 2008.

Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, van Meir E, Tolnay M, Reifenberger G, Merlo A. Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors. PLoS ONE 2(6): e576, 2007.

Failly M, Korur S, Egler V, Boulay JL, Lino MM, Imber R, Merlo A. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 6: 773-781, 2007.

Kneifel S, Bernhardt P, Uusijärvi H, Good S, Plasswilm L, Buitrago-Téllez C, Mueller-Brand J, Maecke H, Merlo A. Individual Voxelwise Dosimetry of Targeted 90Y-labelled Substance P Radiotherapy for Malignant Gliomas. Eur J Nucl Med Mol Imaging Jan 31, 2007.

Kneifel S, Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, Arnold M, Mueller-Brand J, Maecke HR, Reubi JC, Merlo A. Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P. Clin Cancer Res 12: 3843-3850, 2006.

Taschner CA, Wetzel SG, Tolnay M, Froehlich J, Merlo A, Radue EW. Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors. Am J Roentgenol 185: 1477-1486, 2005.

Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5: 2340-2350, 2005.

Beutler D, Avoledo P, Reubi JC, Maecke HR,Mueller-Brand J, Merlo A, Kuehne Th. Three-Year Recurrence-Free Survival in a Patient with Recurrent Medulloblastoma After Resection, High-Dose Chemotherapy and, Intrathecal Yttrium-90-Labeled DOTA0-D-Phe1-Tyr3-Octreotide Radiopeptide Brachytherapy. High-dose chemotherapy and targeted radiotherapy for relapsing medulloblastoma. Cancer 103: 869-73, 2005.

Merlo A. Gliomatosis cerebri: Was bringt die initiale Chemotherapie? Info Neurologie & Psychiatrie. Vol. 2, Nr. 5, 2004

Merlo A. Macht das endovaskuläre Einlegen von thrombogenen Platin-Coils das mikrochirurgische Abklippen von cerebralen Aneurysmen überflüssig? Schweiz Med Forum 4: 1299-1301, 2004.

Feng J, Tamaskovic R, Yang Z, Brazil DP, Merlo A, Hess D, Hemmings BA. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 279: 35510-7, 2004.

Merlo A, Bettler B. Glioblastoma on the move. Science STKE 229: 18-19, 2004.

Wessels PH, Twijnstra A, Kubat B, Unmelen MI, Claessen SM, Sciot R, Merlo A, Ramaekers FC, Speel EJ, Hopmann AH. 10q25.3 (DMBT1) copy number changes in astrocytoma grades II and IV. Genes Chromosomes Cancer 39: 22-8, 2004.

Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl: 88, 83-91, 2003.

Merlo A. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurgical Rev 26: 145-58, 2003.

Roelcke U, Hausmann O, Merlo A, Missimer J, Maguire RP, Freitag P, Radu EW, Weinreich R, Gratzl O, Leenders KL. PET imaging drug distribution after intratumoral injection: the case for (124)-I-iododeoxyuridine in malignant gliomas. J Nucl Med 43: 1444-51, 2002.

Knobbe CB, Merlo A, Reifenberger G. PTEN signaling in gliomas. Neuro-Oncology 4, 2002.

Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, Probst A, Gratzl O, Reubi JC, Maecke HR, Mueller-Brand J, Merlo A. Local injection of the [90Y]-labelled peptidic vector DOTATOC to control gliomas of WHO grades II-III - an extended pilot study. Eur J Nucl Med Mol I 29: 486-493, 2002.

Hofer S, Eichhorn K, Freitag P, Reubi JC, Mueller-Brand J, Maecke H, Merlo A. Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA--D-Phe1-Tyr3 octreotide (DOTATOC). Swiss Med Wkly 43/44: 640-644, 2001.

Jones G, Machado J, Tolnay M, Merlo A. PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express FAK.

Jones G, Machado J, Merlo A. Cancer Res 61: 5688-5691, 2001.Loss of FAK inhibits EGFR-dependent migration and induces aggregation of N-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res 61: 4978-4981, 2001.

Rudiger A, Ronsdorf A, Merlo A, Zimmerli W. Dexamethasone treatment of a patient with large bilateral chronic subdural haematomata. Swiss Med Wkly 131: 387, 2001.

Labuhn M, Jones G, Maier D, Zhang Z, Gratzl O, Speel EJ, Van Meir EG, Merlo A. Quantitative real-time PCR does not show selective targeting of p14ARF at the INK4A locus but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas. Oncogene 20: 1103-1109, 2001.

Mollenhauer J, Herbertz S, Homskov U, Tolnay M, Krebs I, Merlo A, Schroder HD, Maier D, Breitling F, Wiemann S, Gröne HJ, Poustka A. DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res 60: 1704-1710, 2000.

Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822, 2000.

Maier D, Jones G, Li X, Schönthal A, Gratzl O, Van Meir EG, Merlo A. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59: 5479-5482, 1999.

Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798-802, 1999.

Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14/ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479, 1999.

Schaller B, Merlo A, Gratzl O, Probst R. Premeatal and retromeatal cerebellopontine angle meningioma. Two distinct clinical entities. Acta Neurochir 141: 465-471, 1999.

Merlo A, Hausmann O, Wasner M, Steiner Ph, Otte A, Freitag P, Reubi JC, Müller-Brand J, Gratzl O, Mäcke HR. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue (90Y)-DOTA-D-Phe1-Tyr3 octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5: 1025-1033, 1999.

Merlo A. Welche Rolle spielt die minimal-invasive endoskopische Chirurgie in der Behandlung von lumbalen Diskushernien? Editorial Praxis 87: 607-609, 1998.

Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, van Meir E, Scott RJ, Merlo A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1: 3331-3335, 1998.

Schaller B, Merlo A, Kirsch E, Lehmann K, Huber PR, Lyrer P, Steck AJ, Gratzl O. Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: a unique case report and review of the literature. British Journal of Cancer: 2385-2389, 1998.

Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, van Meir E, Scott RJ, Merlo A. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 15: 997-1000, 1997.

Merlo A, Jermann E, Hausmann O, Chiquet-Ehrismann R, Probst A, Landolt H, Mäcke H, Müller J, Gratzl O. Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer 71: 810-816, 1997.

Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727, 1996.

Merlo A, Rochlitz C, Scott R. Survival of patients with Turcot's syndrome and glioblastoma [letter]. N Engl J Med 11: 736-737, 1996.

Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nat Med 1: 686-693, 1995.

Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. A novel p16INK4A transcript. Cancer Res 55: 2995-2997, 1995.

Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB. Inactivation of CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.

Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho K, Hedrick L, Bova GS, Issacs W, Schwab D, Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212, 1995.

Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen M.E, Rollins BJ. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55: 6200-6209, 1995.

Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54: 640-642, 1994.

Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54: 2322-2326, 1994.

Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J, Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-416, 1994.

Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin S, Sidransky D. Frequent microsatellite instability in small cell lung cancer. Cancer Res 54: 2098-2101, 1994.

Merlo A, Stula D, Wasner M. Ergebnisse der perkutanen Diskektomie. Deut Med Wochenschr 119: 407-413, 1994.

Merlo A, Filgueira L, Zuber M, Juretic A, Harder F, Gratzl O, De Libero G, Heberer M, Spagnoli GC. T cell receptor V-gene usage in neoplasms of the central nervous system: a comparative analysis in cultured tumor infiltrating and peripheral blood T cells. J Neurosurg 78: 630-637, 1993.

Merlo A, Juretic A, Zuber M, Filgueira L, Lüscher U, Caetano V, Ulrich J, Gratzl O, Heberer M, Spagnoli GC. Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur J Cancer 29A: 2118-2125, 1993.

Filgueira L, Zuber M, Merlo A, Caetano V, Schultz E, Harder F, Spagnoli GC, Heberer M. Cytokine gene transcription in renal cell carcinomas: a polymerase chain reaction study in tumour biopsies. Brit J Surg 80: 1322-1325, 1993.

Filgueira L, Zuber M, Merlo A, Harder F, Heberer M, Spagnoli GC. Effects of different culture protocols on the expression of discrete T-cell receptor variable regions in human tumour infiltrating lymphocytes. Eur J Cancer 29A: 1754-1760, 1993.

Zuber M, Filgueira L, Merlo A, Spagnoli GC, Harder F, Heberer M. Activation of human tumor infiltrating lymphocytes (TIL) with interleukin-2 and solid phase bound anti-CD3 antibody. Langenbecks Arch Chir: 239-245, 1992.

Stula D, Merlo A. Die perkutane Diskektomie aus neurochirurgischer Sicht. Therapiewoche Schweiz 8: 525-528, 1992.

Merlo A, Weder B, Ketz E, Matter L. Locked-in state in Borrelia burgdorferi meningitis. J Neurol 236: 305-306, 1989.

Merlo A, Morant R, Ketz E, Gerig HJ, Senn HJ. Ist das postpunktionelle Syndrom nach Lumbalpunktion vom Nadeldurchmesser abhängig? Schweiz Med Wochenschr 119: 1781-1786, 1989.

Merlo A, Probst, Ch. Ischialgie/Femoralgie mit neurologischen Symptomen bei dekompensierendem Aneurysma der Aorta abdominalis bzw. der Aa. iliacae internae. Aktuel Rheumatol 10: 134-135, 1985.

Buchkapitel, Monographien

Gratzl O, Merlo A. Kapitel 2: Neurochirurgie. In: J. R. Siewert (Hrsg.): Chirurgie, 8th edition, Springer Medizin Verlag, Heidelberg, 2006.

Merlo A, de Tribolet N. Tumore des Hirns und Rückenmarks. In: A. Steck und Ch. Hess (Ed.), Neurologische Pathophysiologie, Bern: Verlag Hans Huber, 2003.

Merlo A, Herman JG. Methylation and inactivation of tumor suppressor genes. In: R. Scott, R. Weber and H.J. Müller (eds.), 2nd international conference on familial cancer, pp.152-160, Basel: Karger. 1996.

Merlo A, Filgueira L, Zuber M, Lüscher U, Caetano V, Schultz E, Juretic A, Gratzl O, Spagnoli G, Heberer M. Nachweis der inhibitorischen Zytokine TGF-b2 und Interleukin-10 bei primären Neoplasien des Zentralnervensystems. In: U. Laffer, R. de Roche and F. Harder (eds.), Modelle interdisziplinären Handelns. Basler Beitr.Chir. , pp. 76-80, Basel: Karger. 1993.

Zuber M, Filgueira L, Merlo A, Lüscher U, Caetano V, Schultz E, Juretic A, Harder F, Spagnoli G, Heberer M. Zytokintranskription in Nierenzellkarzinomen. In: U. Laffer, R. de Roche and F. Harder (eds.), Modelle interdisziplinären Handelns. Basler Beitr.Chir, pp. 81-85, Basel: Karger. 1993.

Filgueira L, Spagnoli GC, Zuber M, Merlo A, Gasser T, Heberer M, Harder F. Differential TCR V gene usage in isolated human infiltrating and autologous peripheral lymphocytes. In: European biotechnology today: the impact of basic science on diagnosis and therapy, pp. 129-135, Andover: Intercept Ltd.. 1992.

Rem J, Merlo A, Mindermann Th, Gratzl O. Safety and efficacy of fraxiparine in neurosurgery. In: V.V. Kakkar (ed.), Focus on DVT in surgery, pp. 50-54, UK: MAC Ltd. 1992.

Merlo A, Weder B, Ketz E. Chronic progressive neurological involvement in Lyme Borreliosis. In: Lyme Borreliosis II, pp. 213-219, G.Fischer. 1989.

Merlo A. Edgar Michaelis (1890-1967). Kritiker Freuds, Leben und Werk. Inauguraldissertation. Zürcher Medizingeschichtliche Abhandlungen. Heft. Nr.198. Zürich: Juris Druck und Verlag, 1988.